CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 25 enrolled
Drug / intervention
HemoCare™ Hemodialysis Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04198012
NCT04198012N/ACompleted

An Open Label Study to Allow Patients Continuous Use of the HemoCare™ Hemodialysis System for Home Hemodialysis Prior to Market Authorization

Deka Research and Development·interventional·Posted Dec 13, 2019·Updated Sep 8, 2025

In Brief

A clinical study evaluating HemoCare™ Hemodialysis System for End Stage Renal Disease. Completed, enrolled 25 participants across 7 sites.

Detailed Summary

This study is designed to monitor and assess the safety of continued access to the HemoCare™ Hemodialysis System used during the review of the pre-market notifications for the devices in the HemoCare™ Hemodialysis System.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedDec 13, 2019
Enrollment StartDec 16, 2019
Primary CompletionApr 5, 2024
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 6.6 years ago

Interventions

HemoCare™ Hemodialysis Systemdevice

The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self-care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.